Xencor Announces Promising Phase 1 Study Results

The latest announcement is out from Xencor ( (XNCR) ).

On April 29, 2025, Xencor announced interim results from its Phase 1 dose-escalation study of XmAb942 (Xtend™ TL1A), highlighting its potential for treating inflammatory bowel disease (IBD). The company also shared preclinical data from its XmAb TL1A x IL23p19 program, suggesting promising clinical timelines. These developments underscore Xencor’s strategic focus on advancing its XmAb drug candidates, potentially strengthening its position in the biotechnology sector and offering new therapeutic options for stakeholders.

Spark’s Take on XNCR Stock

According to Spark, TipRanks’ AI Analyst, XNCR is a Underperform.

Xencor’s stock score reflects significant financial challenges, particularly with revenue and profitability. The bearish technical indicators further highlight negative sentiment. However, the recent addition of an experienced board member may offer strategic benefits moving forward.

To see Spark’s full report on XNCR stock, click here.

More about Xencor

Xencor, Inc. operates in the biotechnology industry, focusing on the development of engineered antibodies to address complex biological problems. The company specializes in XmAb technology, which enhances native immune functions and optimizes the structure of molecules for therapeutic purposes. Xencor’s portfolio includes a range of drug candidates targeting oncology and autoimmune diseases, with multiple partnerships expanding its reach in the market.

YTD Price Performance: -55.44%

Average Trading Volume: 755,083

Technical Sentiment Signal: Buy

Current Market Cap: $754.2M

See more insights into XNCR stock on TipRanks’ Stock Analysis page.